<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745679</url>
  </required_header>
  <id_info>
    <org_study_id>RC12_0171</org_study_id>
    <nct_id>NCT01745679</nct_id>
  </id_info>
  <brief_title>Pharmacological Study of High Doses of Ceftriaxone in Meningitidis</brief_title>
  <official_title>Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to describe the concentrations of Ceftriaxone at the steady state, in
      patients treated for meningitis, to determine pharmacokinetic parameters at high dose in this
      population. Additionally, we aimed to detect adverse effect, especially neurological trouble
      related to Ceftriaxone toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Day 0 : onset of treatment by Ceftriaxone, following usual therapeutic process (French
      Guideline) From Day 0 to Day 4 : inclusion, clinical and biological data collection,
      electroencephalogram at baseline.

      Two samples for ceftriaxone concentration monitoring :

        -  Trough concentration of ceftriaxone at steady state

        -  A random sample (population PK) At the end of ceftriaxone treatment : assessment of
           tolerance and efficacy of the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasmatic concentration of ceftriaxone, measured at the steady state (after 48 hours of treatment at least).</measure>
    <time_frame>after at least 48 hours of ceftriaxone treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological troubles</measure>
    <time_frame>participants will be followed for the duration of ceftriaxone treatment, an expected average of two weeks</time_frame>
    <description>Neurological troubles explored by electroencephalogram aiming to diagnose epileptic syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical evolution</measure>
    <time_frame>participants will be followed for the duration of ceftriaxone treatment, an expected average of 2 weeks</time_frame>
    <description>Time of return to apyrexia, health complications and lenght of hospital stay will be registered.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Meningitis</condition>
  <condition>Neurological Infections</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ceftriaxone will be administered à high dose : &gt; or equal to 75mg/kg/day or 4 gr/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone treatment</intervention_name>
    <description>ceftriaxone will be administered à high dose : &gt; or equal to 75mg/kg/day or 4 gr/day</description>
    <arm_group_label>Ceftriaxone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized adults patients,

          -  age equal or above 18

          -  Patients with Community or surgical acquired neurological infections, meningitis and
             others

          -  Prescription of ceftriaxone &gt;75mg/kg/d or &gt;4g/d -

          -  Subjects affiliated to French health insurance (social security)

          -  Informed consent form signed

        Exclusion Criteria:

        - Patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nantes Universitary Hospital</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angers Universitary Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Roche/Yon hospital</name>
      <address>
        <city>La Roche/Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poitiers Universitary hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes Universitary hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Nazaire hospital</name>
      <address>
        <city>St Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours universitary hospital</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ceftriaxone</keyword>
  <keyword>Adverse drug effects</keyword>
  <keyword>Therapeutic monitoring</keyword>
  <keyword>Meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

